Genome-wide screening for drug discovery and companion diagnostics

Bibliography

• GUTTMACHER AE, COLLINS FS: Realizing the promise of genomics in biomedical research. JAMA (2005) 294(11):1399-1402.
   PubMed Web of Science ®Google Scholar
• BOOTH B, ZEMMEL R: Prospects for productivity. Nat. Rev. Drug Discov. (2004) 3(5):451-457.
   PubMed Web of Science ®Google Scholar
• YANG TP, CHANG TY, LIN CH, HSU MT, WANG HW: ArrayFusion: a web application for multi-dimensional analysis of CGH, SNP and microarray data. Bioinformatics (2006) 22(21):2697-2698.
   PubMed Web of Science ®Google Scholar
• LIU Y, SHIN S, ZENG X et al.: Genome wide profiling of human embryonic stem cells (hESCs), their derivatives and embryonal carcinoma cells to develop base profiles of US Federal government approved hESC lines – art. no. 20. BMC Dev. Biol. (2006) 6:20.
   PubMedGoogle Scholar
• ROSES AD, BURNS DK, CHISSOE S, MIDDLETON L, ST JEAN P: Disease-specific target selection: a critical first step down the right road. Drug Discov. Today (2005) 10(3):177-189.
   PubMed Web of Science ®Google Scholar
• SPRAGGS CF, PILLAI SG, DOW D et al.: Pharmacogenetics and obesity: common gene variants influence weight loss response of the norepinephrine/doparnine transporter inhibitor GW320659 in obese subjects. Pharmacogenetics Genomics (2005) 15(12):883-889.
   PubMed Web of Science ®Google Scholar
• ROSES AD. Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat. Rev. Genet. (2004) 5(9):645-656.
   PubMed Web of Science ®Google Scholar
• RISNER ME, SAUNDERS AM, ALTMAN JFB et al.: Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease. Pharmacogenomics J. (2006) 6(4):246-254.
   PubMed Web of Science ®Google Scholar
• SMITH R: Peer review: a flawed process at the heart of science and journals. J. Royal Soc. Med. (2006) 99(4):178-182.
   PubMed Web of Science ®Google Scholar
• BONETTA L: Growing pains for NIH grant review. Cell (2006) 125(5):823-825.
   PubMed Web of Science ®Google Scholar
• CUMMINGS JL, VINTERS HV, COLE GM, KHACHATURIAN ZS: Alzheimer’s disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology (1998) 51(1 Suppl. 1):S2-S17; discussion S65-S67.
   PubMed Web of Science ®Google Scholar
• STRITTMATTER WJ, SAUNDERS AM, SCHMECHEL D et al.: Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer’s disease. Proc. Natl. Acad. Sci. USA (1993) 90(5):1977-1981.
   PubMed Web of Science ®Google Scholar
• SAUNDERS AM, STRITTMATTER WJ, SCHMECHEL D et al.: Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology (1993) 43(8):1467-1472.
   PubMed Web of Science ®Google Scholar
• CORDER EH, SAUNDERS AM, STRITTMATTER WJ et al.: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science (1993) 261(5123):921-923.
   PubMed Web of Science ®Google Scholar
• KAMBOH MI: Apolipoprotein E polymorphism and susceptibility to Alzheimer’s disease. Hum. Biol. (1995) 67(2):195-215.
   PubMed Web of Science ®Google Scholar
• WOODCOCK J: FDA introductory comments: clinical studies design and evaluation issues. Clin. Trials (2005) 2(4):273-275.
   Google Scholar
• TEMPLE RJ: Enrichment designs: efficiency in development of cancer treatments. J. Clin. Oncol. (2005) 23(22):4838-4839.
   PubMed Web of Science ®Google Scholar
• ROSES AD: 2025: the practice of neurology: back from the future. Arch. Neurol. (2001) 58(11):1766-1768.
   PubMed Web of Science ®Google Scholar
• SAWCER SJ, MARANIAN M, SINGLEHURST S et al.: Enhancing linkage analysis of complex disorders: an evaluation of high-density genotyping. Hum. Mol. Genet. (2004) 13(17):1943-1949.
   PubMed Web of Science ®Google Scholar
• GOODE EL, JARVIK GP: Assessment and implications of linkage disequilibrium in genome-wide single-nucleotide polymorphism and microsatellite panels. Genet. Epidemiol. (2005) 29(Suppl. 1):S72-S76.
   PubMed Web of Science ®Google Scholar
• NORTHRUP J: The Pharmaceutical Sector. In: The business of health care innovation. Burns LR (Ed), Cambridge University Press, UK (2005):27-102.
   Google Scholar
• ROWINSKY EK: Curtailing the high rate of late-stage attrition of investigational therapeutics against unprecedented targets in patients with lung and other malignancies. Clin. Cancer Res. (2004) 10(12 Pt. 2):4220s-4226s.
   PubMed Web of Science ®Google Scholar
• ROSES AD, SAUNDERS AM, HUANG Y, STRUM J, WEISGRABER KH, MAHLEY RW: Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer’s disease). Pharmacogenomics J. (2006):1-19.
   PubMed Web of Science ®Google Scholar
• PEARSON SD, RAWLINS MD: Quality, innovation, and value for money: NICE and the British National Health Service. JAMA (2005) 294(20):2618-2622.
   PubMed Web of Science ®Google Scholar
• PAPADOPOULOS N, KINZLER KW, VOGELSTEIN B: The role of companion diagnostics in the development and use of mutation-targeted cancer therapies. Nat. Biotechnol. (2006) 24(8):985-995.
   PubMed Web of Science ®Google Scholar
• FRUEH FW, GOODSAID F, RUDMAN A, HUANG SM, LESKO LJ: The need for education in pharmacogenomics: a regulatory perspective. Pharmacogenomics J. (2005) 5(4):218-220.
   PubMed Web of Science ®Google Scholar
• SALERNO RA. LESKO LJ: Three years of promise, proposals, and progress on optimizing the benefit/risk of medicines: a commentary on the 3rd FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshop. Pharmacogenomics J. (2006) 6(2):78-81.
   PubMed Web of Science ®Google Scholar
• FRUEH FW, RUDMAN A, SIMON K, GUTMAN S, REED C, DORNER AJ: Experience with voluntary and required genomic data submissions to the FDA: summary report from track 1 of the third FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshop. Pharmacogenomics J. (2006) 6(5):296-300.
   PubMed Web of Science ®Google Scholar
• FRUEH FW, GURWITZ D: From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community. Pharmacogenomics (2004) 5(5):571-579.
   PubMed Web of Science ®Google Scholar
• MCLEOD HL, YU J: Cancer pharmacogenomics: SNPs, chips, and the individual patient. Cancer Investig. (2003) 21(4):630-640.
   PubMed Web of Science ®Google Scholar
• SIMON R, WANG SJ: Use of genomic signatures in therapeutics development in oncology and other diseases. Pharmacogenomics J. (2006) 6(3):166-173.
   PubMed Web of Science ®Google Scholar
• AMLER LC, GODDARD AD, HILLAN KJ: Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors. Cold Spring Harbor Symposia on Quantitative Biology (2005) 70:483-488.
   Google Scholar
• LARGILLIER R, ETIENNE-GRIMALDI MC, FORMENTO JL et al.: Pharmacogenetics of capecitabine in advanced breast cancer patients. Clin. Cancer Res. (2006) 12(18):5496-502.
   PubMed Web of Science ®Google Scholar
• GIBSON N, JAWAID A, MARCH R et al.: Novel technology and the development of pharmacogenetics within the pharmaceutical industry. Pharmacogenomics (2005) 6(4):339-356.
   PubMed Web of Science ®Google Scholar
• CARDON LR, IDURY RM, HARRIS TJ et al.: Testing drug response in the presence of genetic information: sampling issues for clinical trials. Pharmacogenetics (2000) 10(6):503-510.
   PubMedGoogle Scholar
• KUBOTA T, CHIBA K, ISHIZAKI T: Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin. Pharmacol. Ther. (1996) 60(6):661-666.
   PubMed Web of Science ®Google Scholar
• ZAKS TZ, AKKARI A, BRILEY L et al.: Role of pharmacogenetic studies in early clinical development: Phase I studies with lapatinib. J. Clin. Oncol. (2006) ASCO Ann. Meet. Proc. (Post-Meeting Edn). 24(185, June 20 Suppl.):3029.
   Google Scholar
• CUSATIS G, GREGORC V, LI J et al.: Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J. Natl. Cancer Inst. (2006) 98:1739-1742.
   PubMed Web of Science ®Google Scholar
• LAI E, RILEY J, PURVIS I, ROSES A: A 4-Mb high-density single nucleotide polymorphism-based map around human APOE. Genomics (1998) 54(1):31-38.
   PubMed Web of Science ®Google Scholar
• ST GEORGE-HYSLOP PH, PETIT A: Molecular biology and genetics of Alzheimer’s disease. Comptes Rendus Biologies (2005) 328(2):119-130.
   PubMed Web of Science ®Google Scholar
• MAHLEY RW, WEISGRABER KH, HUANG Y: Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer’s disease. Proc. Natl. Acad. Sci. USA (2006) 103(15):5644-5651.
   PubMed Web of Science ®Google Scholar
• ROSES AD, SAUNDERS AM: Perspective on a pathogenesis and treatment of Alzheimer’s disease. Alzheimer’s & Dementia: J. Alzheimer’s Assoc. (2006) 2:59-70.
   PubMedGoogle Scholar
• EINSTEIN G, BURANOSKY R, CRAIN BJ: Dendritic pathology of granule cells in Alzheimer’s disease is unrelated to neuritic plaques. J. Neurosci. (1994) 14(8):5077-5088.
   PubMed Web of Science ®Google Scholar
• JOHNSON S: The ghost map: the story of London’s most terrifying epidemic-and how it changed science, cities, and the modern world. Penguin Group USA (2006) 320:15.
   Google Scholar
• BEGLEY S: Playing catch-up after lost times in Alzheimer’s labs. Science roundup. Wall Street J. 24 November 2006.
   Google Scholar